Psychedelics Stocks to Watch (Updated 2022)

There is a new sector in the market, rivaling technology, industrial and financial firms. One of these companies could grow and pass other market leaders.  It may be a new thing beyond crypto and blockchain.

While there are those that dabble in financial fantasy, the ones who seem to be making money are the promoters who are charging top dollar for education and training in the new "CURRENCY".

Other late-breaking news is Virtual Reality also called the "Metaverse" Mark Zuckerberg parlayed Facebook into a much large market, the Metaverse, now hawking new hardware and software.  His clever move to buy Oculus signals a paradigm shift for social media. Users will be able to enter a virtual room and see all participants in 3D.  VR goes far beyond video streaming, and webinars online.

The psychedelics market continues to grow, and investors are looking for opportunities. This comprehensive list outlines psychedelics stocks to watch.

The small-cap market has been invaded by a flurry of psychedelics stocks to watch thanks to new company launches. Investors now have a variety of options for taking a run in the shroom stocks space.

In an effort to expand the capabilities of the medical field, companies are starting to investigate the potential of psychedelic medicines and are looking to raise capital in the public market.

While this industry is still in its early stages, the promising potential of psychedelic medicine drug products has attracted the interest of savvy investors eager for an emerging investment opportunity.

A shroom boom is in the works, led by encouraging results from psychedelic medicine treatments for various issues associated with mental health, and in connection to potential global law changes.

Here the Investing News Network presents a current list of psychedelics stocks to watch. The following stocks are all listed on public stock exchanges and are arranged alphabetically.

Aion Therapeutic (CSE:AION,OTC Pink:ANTCF)

Company Profile

Aion Therapeutic is in the business of research and development, treatment, data mining and state-of-the-art artificial intelligence techniques. It is focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations and other medicinal plants in a legal environment for this type of discovery.

Albert Labs (CSE:ABRT)

Press Releases

Company Profile

Albert Labs is Vancouver-based research and drug-development company focused on improving patient access to innovative mental health medications. The company is presently developing a natural psilocybin-based medication for patients with cancer-related distress.

Algernon Pharmaceuticals (CSE:AGN,OTCQB:AGNPF)

Company Profile

Algernon Pharmaceuticals is a clinical-stage drug-development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough.

Allied (OTCQB:ALID)

Company Profile

Allied has both cannabinoid and psilocybin products in the pharmaceutical development track, and is seeking pharma drug indications for depression, anxiety and post-traumatic stress disorder.

ATAI Life Sciences (NASDAQ:ATAI)

Company Profile

ATAI Life Sciences is a clinical-stage biopharma company aiming to transform mental health disorder treatment.

For the remainder click below

Psychedelics Stocks to Watch (Updated 2022)